Main menu


HeartBeam Appoints Ken Persen as Chief Technology Officer

featured image

Santa Clara, California–(business wire) — HeartBeam, Inc. (NASDAQ: BEAT), a development-stage digital healthcare company with proprietary ECG telemedicine technology to detect heart attacks, today appointed Ken Persen as Chief Technology Officer announced that Persen has extensive technical, executive and start-up experience in the healthcare and cardiac device industries. He will lead the overall technology strategy and development of the HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms.

“I am very excited to join the HeartBeam team and lead the development of the first-of-its-kind remote 3D vector ECG technology,” said Persen. “HeartBeam’s technology’s promise to radically change the way patients and healthcare professionals manage heart attack symptoms is even more compelling.”

Persen has over 25 years of experience in the digital healthcare and cardiac device industry. Most recently, Persen founded digital health company LIVMOR, Inc., where he served as Chief Technology Officer. Persen began his career in the cardiac rhythm device industry with software engineering and development roles at his Guidant Corporation and Cameron Health, which were acquired by Boston Scientific. Then, before founding LIVMOR, she held leadership roles in medical informatics devices and systems providing electronic health care.

Dr. Branislav Vaidić said: CEO and Founder of HeartBeam. He brings a deep knowledge of innovation and technology combined with industry insight to support the continued development and evolution of HeartBeam’s technology. ”

About Heartbeam Co., Ltd.

HeartBeam, Inc. (NASDAQ: BEAT) is a development-stage digital healthcare company redefining how outpatient, high-risk cardiovascular diagnosis is made anytime, anywhere with proprietary ECG telemedicine technology. . Its breakthrough solution employs a reusable, credit-card-sized 3D vector ECG recording device and cloud-based software that can help physicians diagnose a wide range of cardiovascular diseases. HeartBeam will initially focus on a large unmet need to help diagnose heart attacks in non-medical patients. Single-lead ECG technology cannot provide this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease who are at high risk of heart attack. For more information, please visit

Forward-Looking Statements

All statements in this release that are not based on historical facts are “forward-looking statements.” Management has based the forward-looking statements contained in this release on its current expectations, and the information on which such expectations are based is subject to change. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from forward-looking statements. It may result from a variety of factors, including the risks and uncertainties described in Risk Factors and Management’s Financial Discussions and Analysis. The Operating Status and Results section of our Forms 10-K, 10-Q and other reports filed with the SEC and available at We strongly advise you to consider these risks and uncertainties when evaluating any forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Except as otherwise required by federal securities laws, we reserve the right to update or revise any forward-looking statements contained herein (or elsewhere) to reflect changes in our expectations or changes in events relating thereto. disclaims any obligation or promise to release publicly to , the conditions or circumstances upon which such statements are based.